EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development

Etelka Pöstyéni, Róbert Gábriel, Andrea Kovács-Valasek

Pharmaceutics · 11.10.2024 · 16 (10) · 1320

DOI: 10.3390/pharmaceutics16101320 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 11.10.2024. Verfasst von Etelka Pöstyéni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Zoology and Neurobiology, University of Pécs, Ifjúság útja 6, 7624 Pécs, Hungary. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TKP, TKP-2021-EGA-16.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Owing to its promiscuous roles, poly (ADP-ribose) polymerase-1 (PARP-1) is involved in various neurological disorders including several retinal pathologies. Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus affecting the retina. In the present review, we highlight the importance of PARP-1 participation in pathophysiology of DR and discuss promising potential inhibitors for treatment. A high glucose level enhances PARP-1 expression; PARP inhibitors have gained attention due to their potential therapeutic effects in DR. They target different checkpoints (blocking nuclear transcription factor (NF-κB) activation; oxidative stress protection, influence on vascular endothelial growth factor (VEGF) expression, impacting neovascularization). Nowadays, there are several improved clinical PARP-1 inhibitors with different allosteric effects. Combining PARP-1 inhibitors with other compounds is another promising option in DR treatments. Besides pharmacological inhibition, genetic disruption of the PARP-1 gene is another approach in PARP-1-initiated therapies. In terms of future treatments, the limitations of single-target approaches shift the focus onto combined therapies. We emphasize the importance of multi-targeted therapies, which could be effective not only in DR, but also in other ischemic conditions.

Schlagwörter

Stichwörter der Autor:innen

PARP-1diabetic retinopathyretinatherapy

Autor:innen und Institutionen

  • Department of Experimental Zoology and Neurobiology, University of Pécs, Ifjúság útja 6, 7624 Pécs, Hungary.
  • János Szentágothai Research Centre, Ifjúság útja 20, 7624 Pécs, Hungary.

Förderung

  • TKP
  • TKP-2021-EGA-16

Zitieren

APA

Pöstyéni, E., Gábriel, R., & Kovács-Valasek, A. (2024). Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development. Pharmaceutics, 16(10), 1320. https://doi.org/10.3390/pharmaceutics16101320

Vancouver

Pöstyéni E, Gábriel R, Kovács-Valasek A. Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development. Pharmaceutics. 2024;16(10):1320. doi:10.3390/pharmaceutics16101320

BibTeX
@article{Pstyni2024,
  author = {Pöstyéni, Etelka and Gábriel, Róbert and Kovács-Valasek, Andrea},
  title = {Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {10},
  pages = {1320},
  doi = {10.3390/pharmaceutics16101320}
}
Kostenlos starten →